Products billed under this code include Abecma.
The billing unit for this code changed over time, so payment limits from different quarters may not be directly comparable. Check the billing unit column below.
Payment limit per UP TO 510 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS, by effective quarter, 4Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Abecma | Celgene Corporation | 59572-0515-01 | 1 | $575,850.465 |
| Abecma | Celgene Corporation | 59572-0515-02 | 1 | $575,850.465 |
| Abecma | Celgene Corporation | 59572-0515-03 | 1 | $575,850.465 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $575,850.465 | +$7,872.685 | UP TO 510 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted September 17, 2026 |
| 3Q26 | $567,977.78 | +$8,196.699 | UP TO 510 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted September 15, 2026 |
| 2Q26 | $559,781.081 | +$1,699.355 | UP TO 510 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted September 15, 2026 |
| 1Q26 | $558,081.726 | +$763.792 | UP TO 510 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted September 15, 2026 |
| 4Q25 | $557,317.934 | +$16,057.487 | UP TO 510 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted September 8, 2026 |
| 3Q25 | $541,260.447 | +$13,637.985 | UP TO 510 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted March 10, 2026 |
| 2Q25 | $527,622.462 | −$689.965 | UP TO 510 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted March 10, 2026 |
| 1Q25 | $528,312.427 | +$1,724.834 | UP TO 510 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted December 19, 2025 |
| 4Q24 | $526,587.593 | +$23,133.068 | UP TO 510 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted June 11, 2025 |
| 3Q24 | $503,454.525 | – | UP TO 510 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted June 11, 2025 |
| 2Q24 | $484,690.30 | $0.00 | UP TO 460 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted March 11, 2025 |
| 1Q24 | $484,690.30 | +$1,236.64 | UP TO 460 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted December 19, 2024 |
| 4Q23 | $483,453.66 | – | UP TO 460 MILLION AUTOLOGOUS ANTI-BCMA CAR-POSITIVE VIABLE T CELLS | Idecabtagene vicleucel car | v1, posted October 10, 2024 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
